These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 10473099

  • 1. Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium.
    Shinohara H, Killion JJ, Bucana CD, Yano S, Fidler IJ.
    Clin Cancer Res; 1999 Aug; 5(8):2148-56. PubMed ID: 10473099
    [Abstract] [Full Text] [Related]

  • 2. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
    Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ.
    Clin Cancer Res; 1998 Sep; 4(9):2053-63. PubMed ID: 9748119
    [Abstract] [Full Text] [Related]

  • 3. Intensified regression of colon cancer liver metastases in mice treated with irinotecan and the immunomodulator JBT 3002.
    Shinohara H, Bucana CD, Killion JJ, Fidler IJ.
    J Immunother; 2000 Sep; 23(3):321-31. PubMed ID: 10838661
    [Abstract] [Full Text] [Related]

  • 4. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages.
    Bruns CJ, Shinohara H, Harbison MT, Davis DW, Nelkin G, Killion JJ, McConkey DJ, Dong Z, Fidler IJ.
    Cancer Res; 2000 Jan 01; 60(1):2-7. PubMed ID: 10646841
    [Abstract] [Full Text] [Related]

  • 5. Intestinal microflora and digestive toxicity of irinotecan in mice.
    Brandi G, Dabard J, Raibaud P, Di Battista M, Bridonneau C, Pisi AM, Morselli Labate AM, Pantaleo MA, De Vivo A, Biasco G.
    Clin Cancer Res; 2006 Feb 15; 12(4):1299-307. PubMed ID: 16489087
    [Abstract] [Full Text] [Related]

  • 6. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model.
    Cao S, Black JD, Troutt AB, Rustum YM.
    Cancer Res; 1998 Aug 01; 58(15):3270-4. PubMed ID: 9699654
    [Abstract] [Full Text] [Related]

  • 7. Streptomycin alleviates irinotecan-induced delayed-onset diarrhea in rats by a mechanism other than inhibition of β-glucuronidase activity in intestinal lumen.
    Kurita A, Kado S, Matsumoto T, Asakawa N, Kaneda N, Kato I, Uchida K, Onoue M, Yokokura T.
    Cancer Chemother Pharmacol; 2011 Jan 01; 67(1):201-13. PubMed ID: 20354702
    [Abstract] [Full Text] [Related]

  • 8. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Ikuno N, Soda H, Watanabe M, Oka M.
    J Natl Cancer Inst; 1995 Dec 20; 87(24):1876-83. PubMed ID: 7494232
    [Abstract] [Full Text] [Related]

  • 9. Differential regulation of type IV collagenases and metalloelastase in murine macrophages by the synthetic bacterial lipopeptide JBT 3002.
    Kumar R, Xie K, Eue I, Dong Z, Killion JJ, Fidler IJ.
    Int J Immunopharmacol; 2000 Jun 20; 22(6):431-43. PubMed ID: 10727754
    [Abstract] [Full Text] [Related]

  • 10. Role of p53 in irinotecan-induced intestinal cell death and mucosal damage.
    Bowen JM, Gibson RJ, Stringer AM, Chan TW, Prabowo AS, Cummins AG, Keefe DM.
    Anticancer Drugs; 2007 Feb 20; 18(2):197-210. PubMed ID: 17159606
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis.
    Hu ZP, Yang XX, Chan SY, Xu AL, Duan W, Zhu YZ, Sheu FS, Boelsterli UA, Chan E, Zhang Q, Wang JC, Ee PL, Koh HL, Huang M, Zhou SF.
    Toxicol Appl Pharmacol; 2006 Oct 15; 216(2):225-37. PubMed ID: 17015070
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.
    Lima-Júnior RC, Freitas HC, Wong DV, Wanderley CW, Nunes LG, Leite LL, Miranda SP, Souza MH, Brito GA, Magalhães PJ, Teixeira MM, Cunha FQ, Ribeiro RA.
    Br J Pharmacol; 2014 May 15; 171(9):2335-50. PubMed ID: 24428790
    [Abstract] [Full Text] [Related]

  • 18. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
    Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A.
    Jpn J Cancer Res; 1993 Jun 15; 84(6):697-702. PubMed ID: 8340259
    [Abstract] [Full Text] [Related]

  • 19. Re:Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
    Guffroy M, Hodge T.
    J Natl Cancer Inst; 1996 Sep 04; 88(17):1240-1. PubMed ID: 8780636
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.